The American Journal of Managed Care4d
Inebilizumab FDA Approved as First Treatment for IgG4-RD
Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...
C&EN28d
Streamlined High-Throughput Data Analysis Workflow for Antibody-Drug Conjugate Biotransformation Characterization
Common fixed modifications included C-terminal lysine loss and N-terminal glutamine to pyroglutamate conversion. Common IgG glycans were selected as possible glycans. For disulfide connections, any ...
eLife2y
Double NPY motifs at the N-terminus of the yeast t-SNARE Sso2 synergistically bind Sec3 to promote membrane fusion
The structure shows a previously uncharacterized binding site for Sec3 at the N-terminus of Sso2, consisting of two highly conserved triple residue motifs (NPY: Asn-Pro-Tyr). We further reveal that ...